EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Using Dynamic Oral Dosing of Rifapentine and Rifabutin to Simulate Exposure Profiles of Long-Acting Formulations in a Mouse Model of Tuberculosis Preventive Therapy

Yong S Chang, Si-Yang Li, Henry Pertinez, Fabrice Betoudji, Jin Lee, Steven P Rannard iD, Andrew Owen, Eric L Nuermberger iD, Nicole C Ammerman iD

Antimicrobial Agents and Chemotherapy · 2023

DOI: 10.1128/aac.00481-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2023. Verfasst von Yong S Chang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Rifabutin, Latent Tuberculosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, HHS | NIH | National Institute of Allergy and Infectious Diseases, Unitaid.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Administration of tuberculosis preventive therapy (TPT) to individuals with latent tuberculosis infection is an important facet of global tuberculosis control. The use of long-acting injectable (LAI) drug formulations may simplify and shorten regimens for this indication.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RifabutinLatent TuberculosisAnimalsMiceAntitubercular AgentsRifampin

Stichwörter der Autor:innen

Mycobacterium tuberculosislatent tuberculosislong-acting injectablerifabutinrifapentine

Substanzen

rifapentineRifabutinAntitubercular AgentsRifampin

Autor:innen und Institutionen

  • Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Centre of Excellence in Long-Acting Therapeutics (CELT), Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom.
  • Department of Medical Microbiology and Infectious Diseases, University Medical Center Rotterdam, Erasmus MC, Rotterdam, The Netherlands.

ORCID-Profile: Steven P Rannard, Eric L Nuermberger, Nicole C Ammerman

Förderung

  • NIAID NIH HHS
  • HHS | NIH | National Institute of Allergy and Infectious Diseases
  • Unitaid

Zitieren

APA

Chang, Y. S., Li, S. Y., Pertinez, H., Betoudji, F., Lee, J., Rannard, S. P., Owen, A., Nuermberger, E. L., & Ammerman, N. C. (2023). Using Dynamic Oral Dosing of Rifapentine and Rifabutin to Simulate Exposure Profiles of Long-Acting Formulations in a Mouse Model of Tuberculosis Preventive Therapy. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00481-23

Vancouver

Chang YS, Li SY, Pertinez H, Betoudji F, Lee J, Rannard SP, et al. Using Dynamic Oral Dosing of Rifapentine and Rifabutin to Simulate Exposure Profiles of Long-Acting Formulations in a Mouse Model of Tuberculosis Preventive Therapy. Antimicrobial Agents and Chemotherapy. 2023. doi:10.1128/aac.00481-23

BibTeX
@article{Chang2023,
  author = {Chang, Yong S and Li, Si-Yang and Pertinez, Henry and Betoudji, Fabrice and Lee, Jin and Rannard, Steven P and Owen, Andrew and Nuermberger, Eric L and Ammerman, Nicole C},
  title = {Using Dynamic Oral Dosing of Rifapentine and Rifabutin to Simulate Exposure Profiles of Long-Acting Formulations in a Mouse Model of Tuberculosis Preventive Therapy},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2023},
  doi = {10.1128/aac.00481-23}
}
Kostenlos starten →